Payment overview · 2025
General Payments
$7,133.55
249 reported records · 38 companies
Healthcare provider profile · identity verified
Randall Webb, MD
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · TULSA, OK · NPI 1275560708
Verified facts
What the public records show
CMS Open Payments records show Randall Webb, MD received $7,133.55 in general payments during 2025 across 249 reported records.
LivaNova USA, Inc. accounted for 28.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 50 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Gammaked, Nurtec Odt, Qulipta, Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Ubrelvy by this doctor in 2024.
Amneal Pharmaceuticals LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ONGENTYS as an associated drug or biological on 728 records involving 311 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Ongentys by this doctor in 2024.
Amneal Pharmaceuticals LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RYTARY as an associated drug or biological on 200 records involving 121 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Rytary by this doctor in 2024.
Biogen, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TECFIDERA as an associated drug or biological on 28 records involving 22 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Tecfidera by this doctor in 2024.
Kedrion Biopharma, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GAMMAKED as an associated drug or biological on 761 records involving 541 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Gammaked by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Nurtec Odt by this doctor in 2024.
SK Life Science, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XCOPRI as an associated drug or biological on 1992 records involving 782 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Xcopri by this doctor in 2024.
UCB, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Briviact as an associated drug or biological on 13595 records involving 4444 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Briviact by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| LivaNova USA, Inc. | Unresolved — no canonical attribution shown | $2,011.93 | 28.2% | 10 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $1,302.08 | 18.2% | 27 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $353.80 | 5.0% | 23 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $290.36 | 4.1% | 17 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $237.72 | 3.3% | 15 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $225.31 | 3.2% | 18 | 2025 |
| TG Therapeutics, Inc. | Unresolved — no canonical attribution shown | $204.65 | 2.9% | 10 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $198.69 | 2.8% | 9 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $195.54 | 2.7% | 11 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $193.36 | 2.7% | 9 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$182.07 | 2.5% | 10 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $169.40 | 2.4% | 9 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $162.03 | 2.3% | 8 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $152.35 | 2.1% | 8 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $145.36 | 2.0% | 7 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $136.34 | 1.9% | 7 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $112.51 | 1.6% | 6 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $109.04 | 1.5% | 4 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $95.32 | 1.3% | 5 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $82.58 | 1.2% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $72.27 | 1.0% | 5 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $65.86 | 0.9% | 3 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $62.41 | 0.9% | 3 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $43.93 | 0.6% | 3 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $42.93 | 0.6% | 2 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $36.13 | 0.5% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $32.55 | 0.5% | 2 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $30.06 | 0.4% | 2 | 2025 |
| Merz Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $29.56 | 0.4% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $22.13 | 0.3% | 1 | 2025 |
| Cycle Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $20.52 | 0.3% | 1 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $17.71 | 0.2% | 1 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$17.63 | 0.2% | 1 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.49 | 0.2% | 1 | 2025 |
| MDD US Operations, LLC | Unresolved — no canonical attribution shown | $16.97 | 0.2% | 1 | 2025 |
| KYOWA KIRIN, INC. | Unresolved — no canonical attribution shown | $16.02 | 0.2% | 1 | 2025 |
| Life Molecular Imaging Ltd | Unresolved — no canonical attribution shown | $15.17 | 0.2% | 1 | 2025 |
| Kedrion Biopharma, Inc. | Unresolved — no canonical attribution shown | $13.77 | 0.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $5,779.85 | 243 |
| Travel and Lodging | $1,274.78 | 3 |
| Education | $78.92 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VNS Therapy Normalized: vns therapy |
Device | LivaNova USA, Inc. | $1,509.60 | 4 | 2025 |
Source payment records
|
|||||
| VNS THERAPY SENTIVA MODEL 1000 GENERATOR Normalized: vns therapy sentiva model 1000 generator |
Device | LivaNova USA, Inc. | $502.33 | 6 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $353.80 | 23 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $237.72 | 15 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $218.92 | 13 | 2025 |
Source payment records
|
|||||
| BRIUMVI Normalized: briumvi |
Drug | TG Therapeutics, Inc. | $204.65 | 10 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $198.69 | 9 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $196.66 | 12 | 2025 |
Source payment records
|
|||||
| ZEPOSIA Normalized: zeposia |
Drug | Celgene Corporation | $195.54 | 11 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $179.41 | 8 | 2025 |
Source payment records
|
|||||
| Hizentra Normalized: hizentra |
Biological | CSL Behring | $169.40 | 9 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $145.36 | 7 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $142.94 | 12 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $142.94 | 12 | 2025 |
Source payment records
|
|||||
| TYSABRI Normalized: tysabri |
Biological | Biogen, Inc. | $138.28 | 7 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $136.34 | 7 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $128.03 | 7 | 2025 |
Source payment records
|
|||||
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $120.70 | 6 | 2025 |
Source payment records
|
|||||
| PONVORY Normalized: ponvory |
Drug | Vanda Pharmaceuticals Inc. | $109.04 | 4 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $93.78 | 5 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $82.58 | 4 | 2025 |
Source payment records
|
|||||
| PANZYGA Normalized: panzyga |
Biological | PFIZER INC. | $82.37 | 6 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $74.53 | 4 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $72.27 | 5 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $71.44 | 4 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $65.86 | 3 | 2025 |
Source payment records
|
|||||
| HYQVIA Normalized: hyqvia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $62.41 | 3 | 2025 |
Source payment records
|
|||||
| CREXONT Normalized: crexont |
Drug | Amneal Pharmaceuticals LLC | $43.93 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $40.86 | 2 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $36.13 | 2 | 2025 |
Source payment records
|
|||||
| OCTAGAM IMMUNE GLOBULIN (HUMAN) Normalized: octagam immune globulin human |
Drug | PFIZER INC. | $35.61 | 2 | 2025 |
Source payment records
|
|||||
| EPIDIOLEX Normalized: epidiolex |
Drug | JAZZ PHARMACEUTICALS INC. | $30.06 | 2 | 2025 |
Source payment records
|
|||||
| INBRIJA Normalized: inbrija |
Drug | Merz Pharmaceuticals, LLC | $29.56 | 1 | 2025 |
Source payment records
|
|||||
| FABRAZYME Normalized: fabrazyme |
Biological | GENZYME CORPORATION | $28.84 | 1 | 2025 |
Source payment records
|
|||||
| Zilbrysq Normalized: zilbrysq |
Drug | UCB, Inc. | $24.32 | 1 | 2025 |
Source payment records
|
|||||
| SKYCLARYS Normalized: skyclarys |
Drug | Biogen, Inc. | $23.75 | 1 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $20.79 | 1 | 2025 |
Source payment records
|
|||||
| Bafiertam Normalized: bafiertam |
Drug | Cycle Pharmaceuticals Inc | $20.52 | 1 | 2025 |
Source payment records
|
|||||
| Tascenso ODT Normalized: tascenso odt |
Drug | Cycle Pharmaceuticals Inc | $20.52 | 1 | 2025 |
Source payment records
|
|||||
| Gamunex-C Normalized: gamunex c |
Biological | Grifols USA, LLC | $17.71 | 1 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $17.63 | 1 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $17.49 | 1 | 2025 |
Source payment records
|
|||||
| NOURIANZ Normalized: nourianz |
Drug | KYOWA KIRIN, INC. | $16.02 | 1 | 2025 |
Source payment records
|
|||||
| NEURACEQ Normalized: neuraceq |
Drug | Life Molecular Imaging Ltd | $15.17 | 1 | 2025 |
Source payment records
|
|||||
| Ocrevus Normalized: ocrevus |
Biological | Genentech USA, Inc. | $13.95 | 1 | 2025 |
Source payment records
|
|||||
| Albuked Normalized: albuked |
Biological | Kedrion Biopharma, Inc. | $13.77 | 1 | 2025 |
Source payment records
|
|||||
| GAMMAKED Normalized: gammaked |
Biological | Kedrion Biopharma, Inc. | $13.77 | 1 | 2025 |
Source payment records
|
|||||
| KEDRAB Normalized: kedrab |
Biological | Kedrion Biopharma, Inc. | $13.77 | 1 | 2025 |
Source payment records
|
|||||
| KOATE Normalized: koate |
Biological | Kedrion Biopharma, Inc. | $13.77 | 1 | 2025 |
Source payment records
|
|||||
| RhoGAM Ultra-Filtered PLUS Normalized: rhogam ultra filtered plus |
Biological | Kedrion Biopharma, Inc. | $13.77 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| GAMMAKED gammaked |
2025 | Gammaked | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 40 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Amneal Pharmaceuticals LLC Exact reporting entity; no affiliate inference |
2025 | ONGENTYS open payments reported associated product |
CMS Open Payments — General Payments 728 supporting records · 311 recipient NPIs · example record 1220525547 |
Ongentys · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Amneal Pharmaceuticals LLC Exact reporting entity; no affiliate inference |
2025 | RYTARY open payments reported associated product |
CMS Open Payments — General Payments 200 supporting records · 121 recipient NPIs · example record 1220526035 |
Rytary · 2024 Exact normalized brand match · 1 Part D row |
53 | 12 |
| Biogen, Inc. Exact reporting entity; no affiliate inference |
2025 | TECFIDERA open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 22 recipient NPIs · example record 1208304358 |
Tecfidera · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Kedrion Biopharma, Inc. Exact reporting entity; no affiliate inference |
2025 | GAMMAKED open payments reported associated product |
CMS Open Payments — General Payments 761 supporting records · 541 recipient NPIs · example record 1206766586 |
Gammaked · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| SK Life Science, Inc. Exact reporting entity; no affiliate inference |
2025 | XCOPRI open payments reported associated product |
CMS Open Payments — General Payments 1992 supporting records · 782 recipient NPIs · example record 1252276115 |
Xcopri · 2024 Exact normalized brand match · 1 Part D row |
54 | suppressed by CMS |
| UCB, Inc. Exact reporting entity; no affiliate inference |
2025 | Briviact open payments reported associated product |
CMS Open Payments — General Payments 13595 supporting records · 4444 recipient NPIs · example record 1224348489 |
Briviact · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 264 | 46 |
| Primidone | Primidone | 183 | 28 |
| Lamotrigine | Lamotrigine | 164 | 24 |
| Baclofen | Baclofen | 152 | 38 |
| Tizanidine Hcl | Tizanidine Hcl | 134 | 24 |
| Kesimpta Pen | Ofatumumab | 114 | 16 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 110 | 18 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 109 | 19 |
| Alprazolam | Alprazolam | 107 | 13 |
| Modafinil | Modafinil | 106 | 18 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 102 | 18 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 96 | 12 |
| Levetiracetam | Levetiracetam | 92 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 89 | 18 |
| Amantadine | Amantadine Hcl | 88 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 83 | 14 |
| Lacosamide | Lacosamide | 83 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 81 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 73 | 13 |
| Clonazepam | Clonazepam | 73 | 13 |
| Entacapone | Entacapone | 73 | 17 |
| Dimethyl Fumarate | Dimethyl Fumarate | 60 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 57 | 11 |
| Xcopri | Cenobamate | 54 | suppressed |
| Rytary | Carbidopa/Levodopa | 53 | 12 |
| Gilenya | Fingolimod Hcl | 51 | suppressed |
| Pregabalin | Pregabalin | 51 | suppressed |
| Carbamazepine | Carbamazepine | 50 | suppressed |
| Prednisone | Prednisone | 49 | 19 |
| Teriflunomide | Teriflunomide | 48 | suppressed |
| Dalfampridine Er | Dalfampridine | 46 | suppressed |
| Fingolimod | Fingolimod Hcl | 44 | suppressed |
| Topiramate | Topiramate | 44 | 11 |
| Diazepam | Diazepam | 43 | 15 |
| Qulipta | Atogepant | 40 | suppressed |
| Lorazepam | Lorazepam | 39 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 36 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 34 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 31 | suppressed |
| Belsomra | Suvorexant | 30 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 30 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 29 | suppressed |
| Ubrelvy | Ubrogepant | 29 | suppressed |
| Carbamazepine Er | Carbamazepine | 28 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 28 | suppressed |
| Emgality Syringe | Galcanezumab-Gnlm | 27 | suppressed |
| Phenobarbital | Phenobarbital | 27 | suppressed |
| Avonex (4 Pack) | Interferon Beta-1a | 26 | suppressed |
| Bupropion Xl | Bupropion Hcl | 26 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 26 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 25 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 25 | suppressed |
| Ongentys | Opicapone | 25 | suppressed |
| Eszopiclone | Eszopiclone | 24 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 23 | suppressed |
| Temazepam | Temazepam | 23 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 22 | suppressed |
| Zonisamide | Zonisamide | 22 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 21 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 21 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 21 | suppressed |
| Fentanyl | Fentanyl | 19 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 19 | suppressed |
| Vimpat | Lacosamide | 19 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 18 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Briviact | Brivaracetam | 17 | suppressed |
| Copaxone | Glatiramer Acetate | 17 | suppressed |
| Armodafinil | Armodafinil | 16 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 16 | suppressed |
| Octagam | Immun Globg(Igg)/Malt/Iga Ov50 | 16 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 14 | suppressed |
| Gammaked | Immune Globul G/Gly/Iga Avg 46 | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 14 | suppressed |
| Dantrolene Sodium | Dantrolene Sodium | 12 | suppressed |
| Estazolam | Estazolam | 12 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Tecfidera | Dimethyl Fumarate | 12 | suppressed |
| Fycompa | Perampanel | 11 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $7,133.55 · 249 records | LivaNova USA, Inc. | AUSTEDO XR, Albuked, BOTOX, BRIUMVI, Bafiertam, CREXONT, EPIDIOLEX, FABRAZYME, GAMMAKED, Gamunex-C, HYQVIA, Hizentra, INBRIJA, INGREZZA, KEDRAB, KESIMPTA, KISUNLA, KOATE, Leqembi, NEURACEQ, NOURIANZ, NUPLAZID, NURTEC ODT, OCTAGAM IMMUNE GLOBULIN (HUMAN), Ocrevus, Ocrevus Zunovo, PANZYGA, PONVORY, PURIFIED CORTROPHIN GEL, QULIPTA, Qelbree, REXULTI, RhoGAM Ultra-Filtered PLUS, Rystiggo, SKYCLARYS, Sunosi, Symbravo, TYSABRI, Tascenso ODT, UBRELVY, ULTOMIRIS, VALTOCO, VNS THERAPY SENTIVA MODEL 1000 GENERATOR, VNS Therapy, VUMERITY, VYEPTI, VYVGART HYTRULO, ZAVZPRET, ZEPOSIA, Zilbrysq | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Gammaked play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error